MEDICXI VENTURES MANAGEMENT JERSEY LTD
Q1 2022 Form 13-F
ST. HELIER
CIK 0001715579
· Institutional investment manager
Consolidated report · includes
1 manager
since Q4 2022
$369.1M Reported Value Total
Reported value
$369.1M
Quarter over quarter
-11.8%
Holdings
7
Top-10 concentration
100.0%
Filing Structure
Reports holdings for
- De Rubertis Francesco · File #028-19836 · since Q4 2022 · declared by one filing
- Francesco De Rubertis (not a 13F filer in our records) · Q4 2019 – Q3 2022 · declared by one filing
- Ollier Michele (not a 13F filer in our records) · File #028-19835 · Q2 2021 – Q4 2021 · declared by one filing
- Kevin Stuart Johnson (not a 13F filer in our records) · Q4 2019 – Q4 2021 · declared by one filing
- Michele Ollier (not a 13F filer in our records) · Q4 2019 – Q4 2021 · declared by one filing
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Giles Johnstone-Scott
Director
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2022 13F record
Q1 2022 13F filing summary
| Period of report | March 31, 2022 |
|---|---|
| Filed | May 12, 2022 |
| Form | 13F-HR |
| Reported value | $369.1M |
| Positions | 7 |
| Change in reported value | -7.6% |
| New positions | 0 |
| Exited positions | 0 |
| Position turnover | 0.0% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 2, 2026
|
3 | $126.7M |
|
Q2 2026 13F
Filed Aug 4, 2026
|
3 | $177.4M |
|
Q1 2026 13F
Filed Apr 21, 2026
|
4 | $981.8M |
|
Q4 2025 13F
Filed Jan 23, 2026
|
5 | $835.0M |
|
Q3 2025 13F
Filed Oct 17, 2025
|
5 | $744.4M |
|
Q2 2025 13F
Filed Jul 8, 2025
|
5 | $427.3M |
|
Q1 2025 13F
Filed Apr 11, 2025
|
5 | $437.7M |
|
Q4 2024 13F
Filed Jan 23, 2025
|
5 | $529.0M |
|
Q3 2024 13F
Filed Oct 15, 2024
|
4 | $528.9M |
|
Q2 2024 13F
Filed Jul 16, 2024
|
4 | $335.3M |
|
Q1 2024 13F
Filed Apr 15, 2024
|
5 | $449.2M |
|
Q4 2023 13F
Filed Feb 1, 2024
|
5 | $296.2M |
|
Q3 2023 13F
Filed Oct 18, 2023
|
6 | $313.2M |
|
Q2 2023 13F
Filed Jul 19, 2023
|
6 | $356.9M |
|
Q1 2023 13F
Filed Apr 27, 2023
|
6 | $233.4M |
|
Q4 2022 13F
Filed Jan 31, 2023
|
6 | $238.1M |
|
Q3 2022 13F
Filed Oct 25, 2022
|
5 | $240.2M |
|
Q2 2022 13F
Filed Aug 3, 2022
|
6 | $240.8M |
|
Q1 2022 13F
Filed May 12, 2022
|
7 | $369.1M |
|
Q4 2021 13F
Filed Feb 3, 2022
|
7 | $399.6M |
8 earlier quarters on file — choose one from the quarter menu above.
Top 7 holdings · Q1 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CNTA CENTESSA PHARMACEUTICALS PLC | $179.1M | 48.51% |
| 2 | AURA AURA BIOSCIENCES INC | $66.9M | 18.12% |
| 3 | PCVX VAXCYTE INC | $45.6M | 12.35% |
| 4 | MRUS MERUS N V | $42.3M | 11.46% |
| 5 | PHAT PHATHOM PHARMACEUTICALS INC | $28.1M | 7.62% |
| 6 | CMPI CHECKMATE PHARMACEUTICALS IN | $4.8M | 1.3% |
| 7 | OBSVF OBSEVA SA | $2.4M | 0.64% |
Values as reported on the Q1 2022 Form 13F. Every position is in the holdings table below.